Potent anti-inflammatory effect of a novel furan-2,5-dione derivative, BPD, mediated by dual suppression of COX-2 activity and LPS-induced inflammatory gene expression via NF-ΰB inactivation

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1926-1940

  Shin, Ji Sun ^a   Park, Seung Jae ^a   Ryu, Suran ^a   Kang, Han Byul ^a   Kim, Tae Woo ^a   Choi, Jung Hye ^a   Lee, Jae Yeol ^a   Cho, Young Wuk ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

Author keywords

inflammation; LPS; NF B; paw oedema; sepsis; TLR signalling

Indexed keywords

3 (BENZO[D] 1,3 DIOXOL 5 YL) 4 PHENYLFURAN 2,5 DIONE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; I KAPPA B ALPHA; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DNA BINDING; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAW EDEMA; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTIC SHOCK; WESTERN BLOTTING;

EID: 84863178651     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01670.x     Document Type: Article

References (39)

1. Adhikari A, Xu M, Chen ZJ, (2007). Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226.
2. Akaogi J, Nozaki T, Satoh M, Yamada H, (2006). Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 6: 383-394.
3. Akira S, Takeda K, (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499-511.
4. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
5. Basak S, Hoffmann A, (2008). Crosstalk via the NF-kappaB signaling system. Cytokine Growth Factor Rev 19: 187-197.
6. Bhattacharyya S, Gill R, Chen ML, Zhang F, Linhardt RJ, Dudeja PK, et al,. (2008). Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB- interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem 283: 10550-10558.
7. Brown J, Wang H, Hajishengallis GN, Martin M, (2011). TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 90: 417-427.
8. Chang L, Karin M, (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
9. Chaudhry MZ, Wang JH, Blankson S, Redmond HP, (2008). Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) 9: 183-194.
10. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH, (1992). The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107: 660-664.
11. Deeks JJ, Smith LA, Bradley MD, (2002). Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325: 619-629.
12. Doyle SL, O'Neill LA, (2006). Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 72: 1102-1113.
13. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A, (2005). Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 115: 3057-3071.
14. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K, (2007). Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 38: 78-82.
15. Gloire G, Legrand-Poels S, Piette J, (2006). NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-1505.
16. Guha M, Mackman N, (2001). LPS induction of gene expression in human monocytes. Cell Signal 13: 85-94.
17. Hacker H, Karin M, (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13.
18. Hatziieremia S, Gray AI, Ferro VA, Paul A, Plevin R, (2006). The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages. Br J Pharmacol 149: 188-198.
19. Herrero JF, Romero-Sandoval EA, Gaitan G, Mazario J, (2003). Antinociception and the new COX inhibitors: research approaches and clinical perspectives. CNS Drug Rev 9: 227-252.
20. Kraemer SA, Arthur KA, Denison MS, Smith WL, DeWitt DL, (1996). Regulation of prostaglandin endoperoxide H synthase-2 expression by 2,3,7,8,-tetrachlorodibenzo-p-dioxin. Arch Biochem Biophys 330: 319-328.
21. Lappas M, Permezel M, Georgiou HM, Rice GE, (2002). Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol Reprod 67: 668-673.
22. Li Q, Verma IM, (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
23. Lin MW, Tsao LT, Chang LC, Chen YL, Huang LJ, Kuo SC, et al,. (2007). Inhibition of lipopolysaccharide-stimulated NO production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages involving the blockade of MEK4/JNK/AP-1 pathway. Biochem Pharmacol 73: 1796-1806.
24. Liu SF, Malik AB, (2006). NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: L622-L645.
25. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, et al,. (1993). Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 90: 9730-9734.
26. Moon JT, Jeon JY, Park HA, Noh YS, Lee KT, Kim J, et al,. (2010). Synthesis and PGE(2) production inhibition of 1H-furan-2,5-dione and 1H-pyrrole-2,5-dione derivatives. Bioorg Med Chem Lett 20: 734-737.
27. Morris CJ, (2003). Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 225: 115-121.
28. Murakami M, Kudo I, (2004). Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 43: 3-35.
29. Mutoh M, Takahashi M, Wakabayashi K, (2006). Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Curr Pharm Des 12: 2375-2382.
30. O'Connell MA, Bennett BL, Mercurio F, Manning AM, Mackman N, (1998). Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 273: 30410-30414.
31. Omote K, Hazama K, Kawamata T, Kawamata M, Nakayaka Y, Toriyabe M, et al,. (2001). Peripheral nitric oxide in carrageenan-induced inflammation. Brain Res 912: 171-175.
32. Prickett TD, Ninomiya-Tsuji J, Broglie P, Muratore-Schroeder TL, Shabanowitz J, Hunt DF, et al,. (2008). TAB4 stimulates TAK1-TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-kappaB. J Biol Chem 283: 19245-19254.
33. Sakurai H, Miyoshi H, Mizukami J, Sugita T, (2000). Phosphorylation- dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett 474: 141-145.
34. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al,. (2005). TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668-2681.
35. Tegeder I, Pfeilschifter J, Geisslinger G, (2001). Cyclooxygenase- independent actions of cyclooxygenase inhibitors. Faseb J 15: 2057-2072.
36. Tian B, Brasier AR, (2003). Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 58: 95-130.
37. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF, (2002). Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26: 152-159.
38. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ, (2001). TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351.
39. Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, et al,. (2006). Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol 148: 216-225.